Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Infective endocarditis


Published on

Published in: Business

Infective endocarditis

  1. 1. Infective Endocarditis 高雄醫學大學附設醫院 心臟內科
  2. 2. Infective Endocarditis <ul><li>Essential characteristics </li></ul><ul><li>General definitions and epidemiology </li></ul><ul><ul><li>NVE </li></ul></ul><ul><ul><li>I.V. drug abuse </li></ul></ul><ul><ul><li>PVE </li></ul></ul><ul><li>Pathogenesis </li></ul><ul><li>Pathophysiology </li></ul><ul><li>Clinical features </li></ul><ul><li>Treatment </li></ul>
  3. 3. Infective Endocarditis <ul><li>Febrile illness </li></ul><ul><li>Persistent bacteremia </li></ul><ul><li>Characteristic lesion of microbial infection of the endothelial surface of the heart </li></ul><ul><ul><li>Variable in size </li></ul></ul><ul><ul><li>Amorphous mass of fibrin & platelets </li></ul></ul><ul><ul><li>Abundant organisms </li></ul></ul><ul><ul><li>Few inflammatory cells </li></ul></ul>the vegetation
  4. 5. Infective Endocarditis <ul><li>Typically involves the valves </li></ul><ul><ul><li>May involve all structures of the heart </li></ul></ul><ul><ul><ul><li>Chordae tendinae </li></ul></ul></ul><ul><ul><ul><li>Sites of shunting </li></ul></ul></ul><ul><ul><ul><li>Mural lesions </li></ul></ul></ul><ul><ul><li>Infection of vascular shunts, by strict definition, is endarteritis, but lesion is the same </li></ul></ul><ul><li>Majority of cases caused by streptococcus, staphylococcus, enterococcus, or fastidious gram negative cocco-bacillary forms </li></ul>
  5. 6. Infective Endocarditis <ul><li>Gram negative organisms </li></ul><ul><ul><li>P. aeruginosa most common </li></ul></ul><ul><ul><li>HACEK - slow growing, fastidious organisms that may need 3 weeks to grow out of culture </li></ul></ul><ul><ul><ul><li>Haemophilus sp. </li></ul></ul></ul><ul><ul><ul><li>Actinobacillus </li></ul></ul></ul><ul><ul><ul><li>Cardiobacterium </li></ul></ul></ul><ul><ul><ul><li>Eikenella </li></ul></ul></ul><ul><ul><ul><li>Kingella </li></ul></ul></ul>
  6. 7. Infective Endocarditis <ul><li>Acute </li></ul><ul><ul><li>Toxic presentation </li></ul></ul><ul><ul><li>Progressive valve destruction & metastatic infection developing in days to weeks </li></ul></ul><ul><ul><li>Most commonly caused by S. aureus </li></ul></ul><ul><li>Subacute </li></ul><ul><ul><li>Mild toxicity </li></ul></ul><ul><ul><li>Presentation over weeks to months </li></ul></ul><ul><ul><li>Rarely leads to metastatic infection </li></ul></ul><ul><ul><li>Most commonly S. viridans or enterococcus </li></ul></ul>
  7. 8. Infective Endocarditis <ul><li>Case rate may vary between 2-3 cases /100,000 to as high as 15-30/100,000 depending on incidence of i.v. drug abuse and age of the population </li></ul><ul><ul><li>55-75% of patients with native valve endocarditis (NVE) have underlying valve abnormalities </li></ul></ul><ul><ul><ul><li>MVP </li></ul></ul></ul><ul><ul><ul><li>Rheumatic </li></ul></ul></ul><ul><ul><ul><li>Congenital </li></ul></ul></ul><ul><ul><ul><li>ASH or: </li></ul></ul></ul><ul><ul><ul><li>i.v. drug abuse </li></ul></ul></ul>
  8. 9. Infective Endocarditis <ul><li>Case rates </li></ul><ul><ul><li>7-25% of cases involve prosthetic valves </li></ul></ul><ul><ul><li>25-45% of cases predisposing condition can not be identified </li></ul></ul>
  9. 10. Infective Endocarditis <ul><li>Pediatric population </li></ul><ul><ul><li>The vast majority (75-90%) of cases after the neonatal period are associated with an underlying congenital abnormality </li></ul></ul><ul><ul><ul><li>Aortic valve </li></ul></ul></ul><ul><ul><ul><li>VSD </li></ul></ul></ul><ul><ul><ul><li>Tetralogy of Fallot </li></ul></ul></ul><ul><ul><li>Risk of post-op infection in children with IE is 50% </li></ul></ul><ul><li>Microbiology </li></ul><ul><ul><li>Neonates: S. aureus, coag – staph, group B strep </li></ul></ul><ul><ul><li>Older children: 40% strep, S. aureus </li></ul></ul>
  10. 11. Infective Endocarditis <ul><li>Adult population </li></ul><ul><ul><li>MVP – prominent predisposing factor </li></ul></ul><ul><ul><ul><li>High prevalence in population </li></ul></ul></ul><ul><ul><ul><ul><li>2-4% </li></ul></ul></ul></ul><ul><ul><ul><ul><li>20% in young women </li></ul></ul></ul></ul><ul><ul><ul><li>Accounts for 7 – 30% NVE in cases not related to drug abuse or nosocomial infection </li></ul></ul></ul><ul><ul><li>Relative risk in MVP ~3.5 – 8.2, largely confined to patients with murmur, but also increased in men and patients >45 years old </li></ul></ul><ul><ul><ul><li>MVP with murmur – incidence IE 52/100/000 pt. years </li></ul></ul></ul><ul><ul><ul><li>MVP w/o murmur – incidence IE 4.6/100,000 pt. years </li></ul></ul></ul>
  11. 12. Infective Endocarditis <ul><li>Adult population </li></ul><ul><ul><li>Rheumatic Heart Disease </li></ul></ul><ul><ul><ul><li>20 – 25% of cases of IE in 1970’s & 80’s </li></ul></ul></ul><ul><ul><ul><li>7 – 18% of cases in recent reported series </li></ul></ul></ul><ul><ul><ul><li>Mitral site more common in women </li></ul></ul></ul><ul><ul><ul><li>Aortic site more common in men </li></ul></ul></ul><ul><ul><li>Congenital Heart Disease </li></ul></ul><ul><ul><ul><li>10 – 20% of cases in young adults </li></ul></ul></ul><ul><ul><ul><li>8% of cases in older adults </li></ul></ul></ul><ul><ul><ul><li>PDA, VSD, bicuspid aortic valve (esp. in men>60) </li></ul></ul></ul>
  12. 13. Infective Endocarditis <ul><li>Intravenous Drug Abuse </li></ul><ul><ul><li>Risk is 2 – 5% per pt./year </li></ul></ul><ul><ul><li>Tendency to involve right-sided valves </li></ul></ul><ul><ul><ul><li>Distribution in clinical series </li></ul></ul></ul><ul><ul><ul><ul><li>46 – 78% tricuspid </li></ul></ul></ul></ul><ul><ul><ul><ul><li>24 – 32% mitral </li></ul></ul></ul></ul><ul><ul><ul><ul><li>8 – 19% aortic </li></ul></ul></ul></ul><ul><ul><li>Underlying valve normal in 75 – 93% </li></ul></ul><ul><ul><li>S. aureus predominant organism (>50%, 60-70% of tricuspid cases) </li></ul></ul>
  13. 14. Infective Endocarditis <ul><li>Intravenous Drug Abuse </li></ul><ul><ul><li>Increased frequency of gram negative infection such as P. aeruginosa & fungal infections </li></ul></ul><ul><ul><li>High concordance of HIV positivity & IE (27-73%) </li></ul></ul><ul><ul><ul><li>HIV status does not in itself modify clinical picture </li></ul></ul></ul><ul><ul><ul><li>Survival is decreased if CD4 count < 200/mm 3 </li></ul></ul></ul>
  14. 15. Infective Endocarditis <ul><li>Prosthetic Valve Endocarditis (PVE) </li></ul><ul><ul><li>10 – 30% of all cases in developed nations </li></ul></ul><ul><ul><li>Cumulative incidence </li></ul></ul><ul><ul><ul><li>1.4 – 3.1% at 12 months </li></ul></ul></ul><ul><ul><ul><li>3.2 – 5.7% at 5 years </li></ul></ul></ul><ul><ul><li>Early PVE – within 60 days </li></ul></ul><ul><ul><ul><li>Nosocomial ( s. epi predominates) </li></ul></ul></ul><ul><ul><li>Late PVE – after 60 days </li></ul></ul><ul><ul><ul><li>Community ( same organisms as NVE ) </li></ul></ul></ul>
  15. 16. Infective Endocarditis Frequency of preexisting cardiac lesion in Patients with IE   Age (%) Lesion Under 2 years 2-15 years 15-50 years >50 years IVDU adults No known heart disease 50-70 10-15 10-20 10 50-60 Congenital heart disease 30-50 70-80 25-35 15-25 10 Rheumatic heart disease Rare 10 10-15 10-15 10 Degenerative heart disease 0 0 Rare 10-20 Rare Previous cardiac surgery 5 10-15 10-20 10-20 10-20 Previous endocarditis Rare 5 5-10 5-10 10-20
  16. 17. Infective Endocarditis
  17. 18. Organisms Causing Infective Endocarditis
  18. 19. Infective Endocarditis
  19. 20. Infective Endocarditis
  20. 21. IE Clinical Manifestations Systemic Manifestation
  21. 22. Infective Endocarditis <ul><li>Pathology </li></ul><ul><ul><li>NVE infection is largely confined to leaflets </li></ul></ul><ul><ul><li>PVE infection commonly extends beyond valve ring into annulus/periannular tissue </li></ul></ul><ul><ul><ul><li>Ring abscesses </li></ul></ul></ul><ul><ul><ul><li>Septal abscesses </li></ul></ul></ul><ul><ul><ul><li>Fistulae </li></ul></ul></ul><ul><ul><ul><li>Prosthetic dehiscence </li></ul></ul></ul><ul><ul><li>Invasive infection more common in aortic position and if onset is early </li></ul></ul>
  22. 23. Infective Endocarditis <ul><li>Pathogenesis </li></ul>Endothelial damage Platelet-fibrin thrombi Microorganism adherence
  23. 24. Infective Endocarditis <ul><li>Nonbacterial Thrombotic Endocarditis </li></ul><ul><ul><ul><ul><ul><li>Endothelial injury </li></ul></ul></ul></ul></ul><ul><ul><ul><ul><ul><li>Hypercoagulable state </li></ul></ul></ul></ul></ul><ul><ul><li>Lesions seen at coaptation points of valves </li></ul></ul><ul><ul><ul><li>Atrial surface mitral/tricuspid </li></ul></ul></ul><ul><ul><ul><li>Ventricular surface aortic/pulmonic </li></ul></ul></ul><ul><li>Modes of endothelial injury </li></ul><ul><ul><ul><li>High velocity jet </li></ul></ul></ul><ul><ul><ul><li>Flow from high pressure to low pressure chamber </li></ul></ul></ul><ul><ul><ul><li>Flow across narrow orifice of high velocity </li></ul></ul></ul><ul><ul><li>Bacteria deposited on edges of low pressure sink or site of jet impaction </li></ul></ul>Venturi Effect Platelet-fibrin thrombi
  24. 25. Venturi Effect
  25. 26. Conversion of NBTE to IE <ul><li>Frequency & magnitude of bacteremia </li></ul><ul><ul><ul><li>Density of colonizing bacteria </li></ul></ul></ul><ul><ul><ul><ul><ul><li>Oral > GU > GI </li></ul></ul></ul></ul></ul><ul><ul><ul><li>Disease state of surface </li></ul></ul></ul><ul><ul><ul><ul><ul><li>Infected surface > colonized surface </li></ul></ul></ul></ul></ul><ul><ul><ul><li>Extent of trauma </li></ul></ul></ul><ul><li>Resistance of organism to host defenses </li></ul><ul><ul><ul><li>Most aerobic gram negatives susceptible to complement-mediated bactericidal effect of serum </li></ul></ul></ul><ul><ul><ul><li>Tendency to adhere to endothelium </li></ul></ul></ul><ul><ul><ul><ul><ul><li>Dextran producing strep </li></ul></ul></ul></ul></ul><ul><ul><ul><ul><ul><li>Fibronectin receptors on staph, enterococcus, strep, Candida </li></ul></ul></ul></ul></ul>
  26. 27. Pathophysiology <ul><li>Clinical manifestations </li></ul><ul><ul><li>Direct </li></ul></ul><ul><ul><ul><li>Constitutional symptoms of infection (cytokine) </li></ul></ul></ul><ul><ul><li>Indirect </li></ul></ul><ul><ul><ul><li>Local destructive effects of infection </li></ul></ul></ul><ul><ul><ul><li>Embolization – septic or bland </li></ul></ul></ul><ul><ul><ul><li>Hematogenous seeding of infection </li></ul></ul></ul><ul><ul><ul><ul><ul><li>N.B. may present as local infection or persistent fever, metastatic abscesses may be small, miliary </li></ul></ul></ul></ul></ul><ul><ul><ul><li>Immune response </li></ul></ul></ul><ul><ul><ul><ul><ul><li>Immune complex or complement-mediated </li></ul></ul></ul></ul></ul>
  27. 28. Pathophysiology <ul><li>Local destructive effects </li></ul><ul><ul><ul><li>Valvular distortion/destruction </li></ul></ul></ul><ul><ul><ul><li>Chordal rupture </li></ul></ul></ul><ul><ul><ul><li>Perforation/fistula formation </li></ul></ul></ul><ul><ul><ul><li>Paravalvular abscess </li></ul></ul></ul><ul><ul><ul><li>Conduction abnormalities </li></ul></ul></ul><ul><ul><ul><li>Purulent pericarditis </li></ul></ul></ul><ul><ul><ul><li>Functional valve obstruction </li></ul></ul></ul>
  28. 29. Pathophysiology <ul><li>Embolization </li></ul><ul><ul><ul><li>Clinically evident 11 – 43% of patients </li></ul></ul></ul><ul><ul><ul><li>Pathologically present 45 – 65% </li></ul></ul></ul><ul><ul><ul><li>High risk for embolization </li></ul></ul></ul><ul><ul><ul><ul><ul><li>Large > 10 mm vegetation </li></ul></ul></ul></ul></ul><ul><ul><ul><ul><ul><li>Hypermobile vegetation </li></ul></ul></ul></ul></ul><ul><ul><ul><ul><ul><li>Mitral vegetations (esp. anterior leaflet) </li></ul></ul></ul></ul></ul><ul><ul><ul><li>Pulmonary (septic) – 65 – 75% of i.v. drug abusers with tricuspid IE </li></ul></ul></ul>
  29. 30. Clinical Features <ul><li>Interval between index bacteremia & onset of sx’s usually < 2 weeks </li></ul><ul><ul><ul><li>May be substantially longer in early PVE </li></ul></ul></ul><ul><li>Fever most common sign </li></ul><ul><ul><ul><li>May be absent in elderly/debilitated pt. </li></ul></ul></ul><ul><li>Murmur present in 80 – 85% </li></ul><ul><ul><ul><li>Generally indication of underlying lesion </li></ul></ul></ul><ul><ul><ul><li>Frequently absent in tricuspid IE </li></ul></ul></ul><ul><li>Changing murmur </li></ul>
  30. 31. Classical Peripheral Manifestations <ul><li>Less common today </li></ul><ul><li>Not seen in tricuspid endocarditis </li></ul><ul><li>Petechiae most common </li></ul>
  31. 32. Janeway Lesions
  32. 33. Splinter Hemorrhage
  33. 34. Osler’s Nodes
  34. 35. Subconjunctival Hemorrhages
  35. 36. Roth’s Spots
  36. 37. Clinical Features <ul><li>Systemic emboli </li></ul><ul><ul><ul><li>Incidence decreases with effective anti-microbial Rx </li></ul></ul></ul><ul><li>Neurological sequelae </li></ul><ul><ul><ul><li>Embolic stroke 15 – 20% of patients </li></ul></ul></ul><ul><ul><ul><li>Mycotic aneurysm </li></ul></ul></ul><ul><ul><ul><li>Cerebritis </li></ul></ul></ul><ul><li>CHF </li></ul><ul><ul><ul><li>Due to mechanical disruption </li></ul></ul></ul><ul><ul><ul><li>High mortality without surgical intervention </li></ul></ul></ul><ul><li>Renal insufficiency </li></ul><ul><ul><ul><li>Immune complex mediated </li></ul></ul></ul><ul><ul><ul><li>Impaired hemodynamics/drug toxicity </li></ul></ul></ul>
  37. 38. Diagnosis <ul><li>Published criteria for diagnostic purposes in obscure cases </li></ul><ul><li>High index of suspicion in patients with predisposing anatomy or behavior </li></ul><ul><li>Blood cultures </li></ul><ul><li>Echocardiography </li></ul><ul><ul><li>TTE – 60% sensitivity </li></ul></ul><ul><ul><li>TEE – 80 – 95% sensitive </li></ul></ul>
  38. 39. Diagnosis <ul><ul><li>Major criteria : </li></ul></ul><ul><ul><li>Positive blood culture for Infective Endocarditis Typical microorganism consistent with IE from 2 separate blood cultures, as noted below: •  viridans streptococci, Streptococcus bovis , or HACEK group or •  community-acquired Staphylococcus aureus or enterococci, in the absence of a primary focus or Microorganisms consistent with IE from persistently positive blood cultures defined as: •  2 positive cultures of blood samples drawn >12 hours apart, or •  all of 3 or a majority of 4 separate cultures of blood (with first and last sample drawn 1 hour apart) </li></ul></ul><ul><ul><li>Evidence of endocardial involvement </li></ul></ul><ul><ul><li>Positive echocardiogram for IE defined as : •  oscillating intracardiac mass on valve or supporting structures, in the path of regurgitant jets, or on implanted material in the absence of an alternative anatomic explanation, or •  abscess, or •  new partial dehiscence of prosthetic valve </li></ul></ul><ul><ul><li>Or New valvular regurgitation (worsening or changing of preexisting murmur not sufficient) </li></ul></ul>
  39. 40. Diagnosis <ul><li>Minor criteria : </li></ul><ul><li>1.Predisposition : predisposing heart condition or intravenous drug 2. Fever : temperature > 38.4C (100.4?F) 3. Vascular phenomena : </li></ul><ul><li>major arterial emboli, septic pulmonary infarcts, mycotic aneurysm, intracranial hemorrhage, conjunctival hemorrhages, and Janeway lesions 4. Immunologic phenomena : </li></ul><ul><li>glomerulonephritis, Osler's nodes, Roth spots and rheumatoid factor 5. Microbiological evidence : positive blood culture but does not meet a major criterion as noted above¹ or serological evidence of active infection with organism consistent with IE 6. Echocardiographic findings : </li></ul><ul><li>consistent with IE but do not meet a major criterion as noted above ¹ Excludes single positive cultures for coagulase-negative staphylococci, diphtheroids, and organisms that do not commonly cause endocarditis. </li></ul>
  40. 41. Goals of Therapy <ul><li>Eradicate infection </li></ul><ul><li>Definitively treat sequelae of destructive intra-cardiac and extra-cardiac lesions </li></ul>
  41. 42. Antibiotic Therapy <ul><li>Treatment tailored to etiologic agent </li></ul><ul><ul><li>Important to note MIC/MBC relationship for each causative organism and the antibiotic used </li></ul></ul><ul><ul><li>High serum concentration necessary to penetrate avascular vegetation </li></ul></ul>
  42. 43. Antibiotic Therapy <ul><li>Treatment before blood cultures turn positive </li></ul><ul><ul><ul><li>Suspected ABE </li></ul></ul></ul><ul><ul><ul><li>Hemodynamic instability </li></ul></ul></ul><ul><ul><li>Neither appropriate nor necessary in patient with suspected SBE who is hemodynamically stable </li></ul></ul>
  43. 44. Antibiotic Therapy <ul><li>Effective antimicrobial treatment should lead to defervescence within 7 – 10 days </li></ul><ul><ul><li>Persistent fever in: </li></ul></ul><ul><ul><ul><li>IE due to staph, pseudomonas, culture negative </li></ul></ul></ul><ul><ul><ul><li>IE with microvascular complications/major emboli </li></ul></ul></ul><ul><ul><ul><li>Intracardiac/extracardiac septic complications </li></ul></ul></ul><ul><ul><ul><li>Drug reaction </li></ul></ul></ul>
  44. 45. Infective Endocarditis - Principles of Therapy
  45. 46. Microbiologic Cure Rate for Endocarditis Virridan streptococci, group A strep 98 98 Enterococcus 90 >90 S. aureus (young IVDU) 90 >90 S. aureus (elderly patients with underlying disease 50 70 Gram negative aerobic bacilli 40 65 Native Valve Endocarditis Antimicrobial therapy alone Antimicrobial therapy plus Surgery Fungus <5 50
  46. 47. Microbiologic Cure Rate for Endocarditis Prosthetic valve endocarditis Antimicrobial therapy alone Antimicrobial therapy plus Surgery   Early PVE Late PVE Early PVE Late PVE Virridan streptococci, group A strep NA 80 NA 90 Enterococcus NA 60 NA 75 S. aureus 25 40 50 60 Coagulase negative staphylococcus 20 40 60 70 Gram negative aerobic bacilli <10 20 40 50 Fungus <1 <1 30 40
  47. 48. Surgical Treatment of Intra-Cardiac Complications <ul><li>NYHA Class III/IV CHF due to valve dysfunction </li></ul><ul><ul><li>Surgical mortality – 20-40% </li></ul></ul><ul><ul><li>Medical mortality – 50-90% </li></ul></ul><ul><li>Unstable prosthetic valve </li></ul><ul><ul><li>Surgical mortality – 15-55% </li></ul></ul><ul><ul><li>Medical mortality – near 100% at 6 months </li></ul></ul><ul><li>Uncontrolled infection </li></ul>
  48. 49. Surgical Treatment of Intra-Cardiac Complications <ul><li>Unavailable effective antimicrobial therapy </li></ul><ul><ul><li>Fungal endocarditis </li></ul></ul><ul><ul><li>Brucella </li></ul></ul><ul><li>S. aureus PVE with any intra-cardiac complication </li></ul><ul><li>Relapse of PVE after optimal therapy </li></ul>
  49. 50. Surgical Treatment of Intra-Cardiac Complications <ul><li>Relative indications </li></ul><ul><ul><li>Perivalvular extension of infection </li></ul></ul><ul><ul><li>Poorly responsive S. aureus NVE </li></ul></ul><ul><ul><li>Relapse of NVE </li></ul></ul><ul><ul><li>Culture negative NVE/PVE with persistent fever (> 10 days) </li></ul></ul><ul><ul><li>Large (> 10mm) or hypermobile vegetation </li></ul></ul><ul><ul><li>Endocarditis due to highly resistant enterococcus </li></ul></ul>
  50. 51. Prevention <ul><li>Prophylactic regimen targeted against likely organism </li></ul><ul><ul><li>Strep. viridans – oral, respiratory, eosphogeal </li></ul></ul><ul><ul><li>Enterococcus – genitourinary, gastrointestinal </li></ul></ul><ul><ul><li>S. aureus – infected skin, mucosal surfaces </li></ul></ul>
  51. 52. Prevention – the procedure <ul><li>Dental procedures known to produce bleeding </li></ul><ul><li>Tonsillectomy </li></ul><ul><li>Surgery involving GI, respiratory mucosa </li></ul><ul><li>Esophageal dilation </li></ul><ul><li>ERCP for obstruction </li></ul><ul><li>Gallbladder surgery </li></ul><ul><li>Cystoscopy, urethral dilation </li></ul><ul><li>Urethral catheter if infection present </li></ul><ul><li>Urinary tract surgery, including prostate </li></ul><ul><li>I&D of infected tissue </li></ul>
  52. 53. Prevention – the underlying lesion <ul><li>High risk lesions </li></ul><ul><ul><li>Prosthetic valves </li></ul></ul><ul><ul><li>Prior IE </li></ul></ul><ul><ul><li>Cyanotic congenital heart disease </li></ul></ul><ul><ul><li>PDA </li></ul></ul><ul><ul><li>AR, AS, MR,MS with MR </li></ul></ul><ul><ul><li>VSD </li></ul></ul><ul><ul><li>Coarctation </li></ul></ul><ul><ul><li>Surgical systemic-pulmonary shunts </li></ul></ul><ul><li>Intermediate risk </li></ul><ul><ul><li>MVP with murmur </li></ul></ul><ul><ul><li>Pure MS </li></ul></ul><ul><ul><li>Tricuspid disease </li></ul></ul><ul><ul><li>Pulmonary stenosis </li></ul></ul><ul><ul><li>ASH </li></ul></ul><ul><ul><li>Bicuspid Ao valve with no hemodynamic significance </li></ul></ul>Lesions at highest risk
  53. 54. Prevention – the underlying lesion <ul><li>Low/no risk </li></ul><ul><ul><li>MVP without murmur </li></ul></ul><ul><ul><li>Trivial valvular regurg. </li></ul></ul><ul><ul><li>Isolated ASD </li></ul></ul><ul><ul><li>Implanted device (pacer, ICD) </li></ul></ul><ul><ul><li>CAD </li></ul></ul><ul><ul><li>CABG </li></ul></ul>
  54. 55. This wallet card is to be given to patients by their physician. Healthcare professionals, please see back of card for reference to the complete statement. Name: ____________________________________________ needs protection from BACTERIAL ENDOCARDITIS because of an existing HEART CONDITION Diagnosis: __________________________________________ Prescribed by: _______________________________________ Date: ______________________________________________
  55. 56. Chemoprophylaxis <ul><li>Adult Prophylaxis: Dental, Oral, Respiratory, Esophageal </li></ul><ul><li>Standard Regimen </li></ul><ul><ul><li>Amoxicillin 2g PO 1h before procedure or </li></ul></ul><ul><ul><li>Ampicillin 2g IM/IV 30m before procedure </li></ul></ul><ul><li>Penicillin Allergic </li></ul><ul><ul><li>Clindamycin </li></ul></ul><ul><ul><ul><li>600 mg PO 1h before procedure or </li></ul></ul></ul><ul><ul><ul><li>600 mg IV 30m before </li></ul></ul></ul><ul><ul><li>Cephalexin OR Cefadroxil 2g PO 1 hour before </li></ul></ul><ul><ul><li>Cefazolin 1.0g IM/IV 30 min before procedure </li></ul></ul><ul><ul><li>Azithromycin or Clarithromycin 500mg PO 1h before </li></ul></ul>
  56. 57. <ul><li>Adult Genitourinary or Gastrointestinal Procedures </li></ul><ul><li>High Risk Patients </li></ul><ul><ul><li>Standard Regimen </li></ul></ul><ul><ul><ul><ul><li>Before procedure (30 minutes): </li></ul></ul></ul></ul><ul><ul><ul><ul><ul><li>Ampicillin 2g IV/IM AND </li></ul></ul></ul></ul></ul><ul><ul><ul><ul><ul><li>Gentamicin 1.5 mg/kg (MAX 120 mg) IM/IV </li></ul></ul></ul></ul></ul><ul><ul><ul><li>After procedure (6 hours later) </li></ul></ul></ul><ul><ul><ul><ul><li>Ampicillin 1g IM/IV OR </li></ul></ul></ul></ul><ul><ul><ul><ul><li>Amoxicillin 1g PO </li></ul></ul></ul></ul><ul><ul><li>Penicillin Allergic </li></ul></ul><ul><ul><ul><li>Complete infusion 30 minutes before procedure </li></ul></ul></ul><ul><ul><ul><ul><li>Vancomycin 1g IV over 1-2h AND </li></ul></ul></ul></ul><ul><ul><ul><ul><li>Gentamicin 1.5 mg/kg IV/IM (MAX 120 mg) </li></ul></ul></ul></ul><ul><li>Moderate Risk Patients </li></ul><ul><ul><li>Standard Regimen </li></ul></ul><ul><ul><ul><li>Amoxicillin 2g PO 1h before OR </li></ul></ul></ul><ul><ul><ul><li>Ampicillin 2g IM/IV 30m before </li></ul></ul></ul><ul><ul><li>Penicillin Allergic </li></ul></ul><ul><ul><ul><li>Vancomycin 1g IV over 1-2h, complete 30m before </li></ul></ul></ul>
  57. 58. Summary <ul><li>You need to go to medical school (and graduate) in order to take care of patients with endocarditis. </li></ul>
  58. 59. Case presentation <ul><li>M-mode and trans-esophageal echocardiogram showed mobile vegetation at aortic valve </li></ul>
  59. 60. Case presentation <ul><li>Blood culture yield Streptococcal viridans </li></ul><ul><li>Despite deferverscence nearly immediately after penicillin and gentamicin treatment, he developed Rt CVA 4 days after hospitalization </li></ul>